Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system

Author： Le Lay K.   Myon E.   Hill S.   Riou-Franca L.   Scott D.   Sidhu M.   Dunlop D.   Launois R.  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.8, Iss.2, 2007-06, pp. : 145-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing single‐agent with doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2: A meta‐analysis

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : 253-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 293-299

Karger

Access to resources Recommend Favorite

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 710-718

Karger

Access to resources Recommend Favorite

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite